海翔药业(002099.SZ)：参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has announced the initiation of the Phase II clinical trial for its innovative nucleic acid drug NWRD06, aimed at preventing postoperative recurrence of liver cancer, developed by its investee company, Nuo Wei Biotechnology [1] Group 1 - Haisheng Pharmaceutical received a notification from its fund management subsidiary, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [1] - The clinical trial for NWRD06 has officially started at the Cancer Hospital of the Chinese Academy of Medical Sciences [1] - The first subject has been enrolled and has received the initial dose in the trial [1]